NASDAQ:LMNXLuminex Stock Price, Forecast & News

Luminex's stock was trading at $27.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LMNX stock has increased by 14.2% and is now trading at $30.96.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Luminex.

Luminex is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Luminex.

Luminex Co. (NASDAQ:LMNX) released its earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.27 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.19. The medical instruments supplier had revenue of $109.52 million for the quarter, compared to analysts' expectations of $107.33 million. Luminex had a return on equity of 2.38% and a net margin of 3.04%. The company's revenue for the quarter was up 31.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.11) earnings per share.
View Luminex's earnings history.

Luminex declared a quarterly dividend on Tuesday, May 26th. Stockholders of record on Thursday, June 18th will be given a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Wednesday, June 17th.
View Luminex's dividend history.

Luminex issued an update on its third quarter 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $100 million, compared to the consensus revenue estimate of $89.47 million.

2 brokerages have issued twelve-month price objectives for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's share price to reach $26.50 in the next year. This suggests that the stock has a possible downside of 14.4%.
View analysts' price targets for Luminex.

Media coverage about LMNX stock has trended negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Luminex earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Luminex.

Luminex saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,790,000 shares, an increase of 27.9% from the January 31st total of 1,400,000 shares. Based on an average daily trading volume, of 276,800 shares, the days-to-cover ratio is currently 6.5 days. Currently, 4.3% of the shares of the company are short sold.
View Luminex's Short Interest.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Crispr Therapeutics (CRSP), Square (SQ), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE) and Inseego (INSG).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (3.43%), Copeland Capital Management LLC (1.83%), Bank of New York Mellon Corp (1.25%), Investment Management of Virginia LLC (0.96%), Principal Financial Group Inc. (0.78%) and Bank of Montreal Can (0.49%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers and Richard W Rew II.
View institutional ownership trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Great Lakes Advisors LLC, Cowen Prime Services LLC, Bank of New York Mellon Corp, Prudential Financial Inc., Blair William & Co. IL, Bridge City Capital LLC, and State of Tennessee Treasury Department. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex.

LMNX stock was bought by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, Goldman Sachs Group Inc., Grantham Mayo Van Otterloo & Co. LLC, Robeco Institutional Asset Management B.V., Russell Investments Group Ltd., Assenagon Asset Management S.A., Mackay Shields LLC, and Envestnet Asset Management Inc.. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir.
View insider buying and selling activity for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $30.96.

Luminex has a market capitalization of $1.44 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]